Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Global Bile Duct Cancer Drug Market Will Reach USD 262 Million By 2024: Zion Market Research

GlobeNewswire Tuesday, 8 January 2019
According to the report, the global bile duct cancer drug market was valued at approximately USD 168 million in 2017 and is expected to generate revenue of around USD 262 million by 2024, at a CAGR of around 6.6% between 2018 and 2024.

New York, NY, Jan. 08, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled *“Bile Duct Cancer Drug Market by Type (5-fluorouracil (5-FU), Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin, and Others) and by Application (Hospitals, Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024”*. According to the report, the global bile duct cancer drug market was valued at approximately USD 168 million in 2017 and is expected to generate revenue of around USD 262 million by 2024, at a CAGR of around 6.6% between 2018 and 2024.

Bile duct connects the liver to the gallbladder and carries the fluid called bile, which is synthesized by the liver and stored in the gallbladder. The key function of bile is to break fats and help in digestion. The specific cause of bile duct cancer is unknown, but various factors responsible for bile duct cancer are abnormalities in the bile duct, liver inflammation, exposure to harmful chemicals and toxins, etc. The main symptoms of bile duct cancer include weight loss, discoloration of stool and urine, jaundice, loss of appetite, abdominal pain, etc. Some drugs used to treat bile duct cancer include cisplatin (Platinol), fluorouracil (5-FU, Adrucil), oxaliplatin (Eloxatin), capecitabine (Xeloda), gemcitabine (Gemzar), etc.

*Browse through 37 Tables & 12 Figures spread over 110 Pages and in-depth TOC on “Global Bile Duct Cancer Drug Market: By Type, Size, Share, Applications, Growth, Analysis and Forecast, 2017—2024”.*

*Request Free Sample Report of Global Bile Duct Cancer Drug Market Report @ *https://www.zionmarketresearch.com/sample/bile-duct-cancer-drug-market

The major growth driver of the global bile duct cancer drug market is the increase in the prevalence of bile duct cancer patients across the globe. The increasing prevalence of bile duct cancer is fuelling the demand for treatment. The technological advancement has increased over the period which has led to the development of treatment options. Furthermore, the increase in healthcare expenditure due to increased awareness among people is also expected to promote the growth of bile duct cancer drug market.

The bile duct cancer drug market is classified into type and application. By type, this market is divided into 5-fluorouracil (5-FU), gemcitabine, cisplatin, capecitabine, oxaliplatin, and others. The 5-fluorouracil segment is anticipated to hold the largest market share over the forecast years. By application, this market is segmented into hospitals, clinics, and others. Hospitals are expected to hold the largest market share in the forecast time period. 

*Download Free Report PDF Brochure: *https://www.zionmarketresearch.com/requestbrochure/bile-duct-cancer-drug-market

North America is projected to lead the global bile duct cancer drug market. Increased prevalence of bile duct cancer, a large number of ongoing research activities, the quicker and easy product approval process, rising number of awareness programs, and growing government and public-private investments in this region are the key factors driving this regional market. The U.S. and Canada are anticipated to nurture the demand for angiography devices, owing to the increased prevalence of bile duct cancer.

Europe is likely to emerge as the second largest regional market for bile duct cancer drug over the estimated timeframe, owing to the presence of developed economies, advanced healthcare facilities, and technological advancements in the region.

Browse the full *“Bile Duct Cancer Drug Market by Type (5-fluorouracil (5-FU), Gemcitabine, Cisplatin, Capecitabine, Oxaliplatin, and Others) and by Application (Hospitals, Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2017—2024”* Report at https://www.zionmarketresearch.com/report/bile-duct-cancer-drug-market

The Asia Pacific bile duct cancer drug is expected to expand rapidly over the forecast time period. This regional market’s growth can be attributed to a large patient population pool, increasing number of aging population, a rising number of awareness programs, growing incidences of liver infections, and rising fiscal investments by governments and key manufacturers and suppliers of the bile duct cancer drugs across the region.

Some key players of the bile duct cancer drug market include Delcath Systems Inc., Accord Healthcare, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Pfizer Inc., Eli Lilly and Company, Mylan N.V, Fresenius Kabi AG, Intercept Pharmaceuticals, Inc., and Celgene Corporation, among others.

*Inquire more about this report before purchase @ *https://www.zionmarketresearch.com/inquiry/bile-duct-cancer-drug-market

*This report segments the global bile duct cancer drug market into:*

*Global Bile Duct Cancer Drug Market: By Product*

· 5-fluorouracil (5-FU)
· Gemcitabine
· Cisplatin
· Capecitabine
· Oxaliplatin
· Others

*Global Bile Duct Cancer Drug Market: By Application*

· Hospitals
· Clinics
· Others

*Global Bile Duct Cancer Drug Market: By Region*

· North America

· The U.S.

· Europe

· UK
· France
· Germany

· Asia Pacific

· China
· Japan
· India

· Latin America

· Brazil

· The Middle East and Africa

*Related Reports:*

· *Personalized Medicine Market: *https://www.zionmarketresearch.com/report/personalized-medicine-market
· *Cannabis Testing Market: *https://www.zionmarketresearch.com/report/cannabis-testing-market
· *Legal Marijuana Market:* https://www.zionmarketresearch.com/report/legal-marijuana-market
· *Medical Marijuana Market:* https://www.zionmarketresearch.com/report/medical-marijuana-market
· *Ophthalmic Drugs Market:* https://www.zionmarketresearch.com/report/ophthalmic-drugs-market                                                                                           

*About Us:*

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

*Follow Us LinkedIn: *https://www.linkedin.com/company/zion-market-research
*Follow Us Twitter: *https://twitter.com/zion_research

*Blog:* http://usindustrynews.com | http://europeindustrynews.com | http://zmrresearchnews.us | http://zmrnewsanalysis.com

*Contact Us:*

Joel John
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
*Email:* sales@zionmarketresearch.com

*Website:* https://www.zionmarketresearch.com

*Blog:* http://zmrblog.com
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related news from verified sources

Clinigen buys U.S. rights to Novartis' cancer drug Proleukin

British pharmaceutical firm Clinigen Group Plc said on Wednesday it acquired the U.S. rights to Swiss drugmaker Novartis AG's skin and lung cancer drug Proleukin...
Reuters

Bayer stresses drug's tolerability in bid for prostate cancer market

Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer...
Reuters

IEA monthly oil market report: US sanctions on Venezuela may create problems for crude quality, not quantity

The International Energy Agency (IEA), in its monthly oil market report, maintained 019 global oil demand growth forecast of 1.4 million bpd vs. 1.3 million bpd...
FXstreet.com

Genprex adds pharma veteran Joh Bonfiglio to board

Genprex Inc (NASDAQ:GNPX) announced Tuesday the appointment of Dr John N. Bonfiglio Ph.D. to its board of directors. Bonfiglio brings more than 30 years of...
Proactive Investors


Tweets about this


Other recent news in Press Releases

Kornit Digital appoints Andy Yarrow as PRESIDENT of Asia PacificColorado Realtor Beth Baker Owens Educates PEOPLE on Helping Parents Downsize
INFORM SOFTWARE Corporation Expands Management, Appoints Justin Newell Chief Operating OfficerLPA Engineers Recognized for Outstanding Projects by the AMERICAN Society of Civil Engineers
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? Send us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest